Skip to main content

Evommune, Inc 8-K, filed Nov 4, 2026

Evommune, Inc. (EVMN)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

Evommune, Inc filed this 8-K on November 4, 2026.

Evommune licensed EVO570 from Hinova for $20.0 million upfront, warrants, up to $150.0 million in development and regulatory milestones and up to $920.0 million in commercial milestones. A $30.0 million placement is expected to close; estimated liquidity extends into the second half of 2029. AI summary

Items reported

  • Item 1.01: Entered into a material agreement
  • Item 3.02: Unregistered sale of equity
  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events